Fidelity Investments’s Matinas BioPharma MTNB Stock Holding History

Fidelity Investments’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4	Buy	+7	New	+$4	﹤0.01%	5394
2025 Q4	–	Sell	-5	Closed	-$9	–	5528
2025 Q3	$9	Buy	5 +3	+150%	+$4	﹤0.01%	5337
2025 Q2	$2	Buy	2 +1	+100%	+$1	﹤0.01%	5308
2025 Q1	$1	Buy	+1	New	+$1	﹤0.01%	5274
2024 Q2	–	Sell	-100	Closed	-$1.35K	–	5540
2024 Q1	$1.35K	Buy	100 +30	+43%	+$356	﹤0.01%	4753
2023 Q4	$757	Buy	+70	New	+$790	﹤0.01%	4781
2022 Q2	–	Sell	-148	Closed	-$6K	–	5284
2022 Q1	$6K	Buy	+148	New	+$5.45K	﹤0.01%	4386
2021 Q1	–	Hold	0	–	–	–	4341
2020 Q4	–	Hold	0	–	–	–	4135
2019 Q4	–	Sell	-24	Closed	-$1K	–	4094
2019 Q3	$1K	Buy	+24	New	+$867	﹤0.01%	3653

Other funds holding MTNB

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

HIW

Holos Integrated Wealth Kennett Square, Pennsylvania $214M AUM 14.99% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Fidelity Investments's MTNB Position: Q1 2026 in Review

Fidelity Investments opened a new position in Matinas BioPharma (MTNB) in Q1 2026: 7 shares worth $4. The stake represents ﹤0.01% of the portfolio and ranks #5394 among its holdings. This is a return to the name: Fidelity Investments previously reported a position in MTNB as recently as Q3 2025.

Fidelity Investments first reported a position in MTNB in Q3 2019 and has held it in 8 quarters since. The position peaked at $6K in Q1 2022. 28 funds tracked by Wall St. Rank hold MTNB as of Q1 2026.

Fidelity Investments held 7 shares of Matinas BioPharma worth $4 as of Q1 2026.
Matinas BioPharma was a new Fidelity Investments position in Q1 2026.
Matinas BioPharma made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #5394 holding.
Fidelity Investments first reported a position in Matinas BioPharma in Q3 2019 and has held it in 8 quarters since.
Fidelity Investments's Matinas BioPharma position peaked at $6K in Q1 2022.
28 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.